Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure, has opened a new technology center for developing dialysis machines at its Schweinfurt, Germany production and development site. About 220 employees from different departments will work together on a project basis in the new 7,500-square-meter (81,000-square-foot) building, in which the company has invested about €22 million.

Due to the pandemic, the opening ceremony was a purely digital event. The online conference included a video tour through the building. In addition, employees presented their future workstations in the technical, laboratory and testing areas, as well as offices, break spaces and conference rooms.

“As much as virtual cooperation from home office works well: In combination with virtual networking, person-to-person interactions on site are irreplaceable, and so I am really looking forward to the cooperation in our new technology center,” said Johann Brede, Project Director of the technology center. “With short and direct access ways and corridors, and an open structure, the entire building is designed for networking and exchanges between different disciplines and teams. This way, we can develop for our patients even better dialysis machines that will also cost less.”

Construction of the five-floor building, which required some 5,700 cubic meters of concrete and 900 tons of steel, took three years. The technology center is built to modern environmental standards and includes, among other features, a “green roof.”

The plant in Schweinfurt, which was established in 1979, is Fresenius Medical Care’s largest development and production facility for dialysis machines and other medical devices. The company now employs more than 1,200 people in the city in northern Bavaria, about 120 kilometers (75 miles) east of Frankfurt. About a third of them work in research and development.

Dialysis machines are among the most important products for treating chronic kidney disease. During treatment, the dialysis machine pumps the patient’s blood through bloodlines, monitors its circulation through the dialyzer, and adds anti-coagulants. Treatments are generally carried out three times weekly, and take between three and six hours each.

The information and documents contained on the following pages of this website are for information purposes only. These materials do neither constitute an offer nor an invitation to subscribe to or to purchase securities, nor any investment advice or service, and are not meant to serve as a basis for any kind of obligation, contractual or otherwise. Securities may not be offered or sold in the United States of America (“US”) absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. The securities described on the following pages are not offered for sale in the US or to "US persons" (as defined in Regulation S under the US Securities Act of 1933, as amended).

THE FOLLOWING INFORMATION AND DOCUMENTS ARE NOT DIRECTED AT AND ARE NOT INTENDED FOR USE BY (I) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN THE US, CANADA, JAPAN OR AUSTRALIA OR WHO ARE US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), OR (II) PERSONS IN ANY OTHER JURISDICTION WHERE THE COMMUNICATION OR RECEIPT OF SUCH INFORMATION IS RESTRICTED IN SUCH A WAY THAT PROVIDES THAT SUCH PERSONS SHALL NOT RECEIVE IT. SUCH PERSONS, OR PERSONS ACTING FOR THE BENEFIT OF ANY SUCH PERSONS, ARE NOT PERMITTED TO VISIT THE FOLLOWING PAGES OF THE WEBSITE.

To visit the following parts of this website you must confirm that
(i) you are not a resident of the United States of America, Canada, Japan or Australia or a "US person" (as defined in Regulation S under the US Securities Act of 1933, as amended),
(ii) you are not a person to whom the communication of the information contained on the website is restricted,
(iii) you will not distribute any of the information and documents contained thereon to any such person, and
(iv) you are not acting for the benefit of any such person.

By clicking on the "Accept" button below, you will be deemed to have made this confirmation.

Accept Cancel
Submit

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

---

Fresenius today successfully placed bonds with an aggregate volume of €1.5 billion across three tranches:

• €500 million bonds with a maturity in October 2025 and an annual coupon of 0%, 
• €500 million bonds with a maturity in October 2028 and an annual coupon of 0.5% and 
• €500 million bonds with a maturity in October 2031 and an annual coupon of 0.875%.

The proceeds will be used for general corporate purposes, including refinancing of existing financial liabilities. 

The bonds were drawn under the Fresenius Debt Issuance Program (DIP) and issued by Fresenius Finance Ireland plc., a wholly owned subsidiary of Fresenius SE & Co. KGaA. The company has applied to the Luxembourg Stock Exchange to admit the bonds to trading on its regulated market.

The envisaged settlement date is April 1, 2021.

The information and documents contained on the following pages of this website are for information purposes only. These materials do neither constitute an offer nor an invitation to subscribe to or to purchase securities, nor any investment advice or service, and are not meant to serve as a basis for any kind of obligation, contractual or otherwise. Securities may not be offered or sold in the United States of America (“US”) absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. The securities described on the following pages are not offered for sale in the US or to "US persons" (as defined in Regulation S under the US Securities Act of 1933, as amended).

THE FOLLOWING INFORMATION AND DOCUMENTS ARE NOT DIRECTED AT AND ARE NOT INTENDED FOR USE BY (I) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN THE US, CANADA, JAPAN OR AUSTRALIA OR WHO ARE US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), OR (II) PERSONS IN ANY OTHER JURISDICTION WHERE THE COMMUNICATION OR RECEIPT OF SUCH INFORMATION IS RESTRICTED IN SUCH A WAY THAT PROVIDES THAT SUCH PERSONS SHALL NOT RECEIVE IT. SUCH PERSONS, OR PERSONS ACTING FOR THE BENEFIT OF ANY SUCH PERSONS, ARE NOT PERMITTED TO VISIT THE FOLLOWING PAGES OF THE WEBSITE.

To visit the following parts of this website you must confirm that
(i) you are not a resident of the United States of America, Canada, Japan or Australia or a "US person" (as defined in Regulation S under the US Securities Act of 1933, as amended),
(ii) you are not a person to whom the communication of the information contained on the website is restricted,
(iii) you will not distribute any of the information and documents contained thereon to any such person, and
(iv) you are not acting for the benefit of any such person.

By clicking on the "Accept" button below, you will be deemed to have made this confirmation.

Accept Cancel
Submit

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

---

Fresenius today successfully placed bonds with an aggregate volume of €1.5 billion across three tranches:

• €500 million bonds with a maturity in October 2025 and an annual coupon of 0%,
• €500 million bonds with a maturity in October 2028 and an annual coupon of 0.5% and
• €500 million bonds with a maturity in October 2031 and an annual coupon of 0.875%.

The proceeds will be used for general corporate purposes, including refinancing of existing financial liabilities.

The bonds were drawn under the Fresenius Debt Issuance Program (DIP) and issued by Fresenius Finance Ireland plc., a wholly owned subsidiary of Fresenius SE & Co. KGaA. The company has applied to the Luxembourg Stock Exchange to admit the bonds to trading on its regulated market.

The envisaged settlement date is April 1, 2021.

Susanne Zeidler and Dr. Frank Appel proposed for election to the Supervisory Board of Fresenius Management SE

Michael Sen (52) will become the new Chief Executive Officer of Fresenius Kabi AG. The Supervisory Board of Fresenius Management SE has unanimously appointed him to the Management Board of Fresenius effective on April 12, 2021. He succeeds Mats Henriksson (53), who is leaving the company due to different views on Fresenius Kabi’s future direction.

Michael Sen was a member of the Management Board of Siemens AG from April 2017 to March 2020, where he was responsible for the healthcare business Siemens Healthineers and for Siemens’ energy business. Prior to that, from 2015 to 2017, he was Chief Financial Officer of E.ON SE. At the start of his professional career, Michael Sen completed an apprenticeship at Siemens in Berlin and then studied business administration at the Technical University of Berlin. After graduation, he took on various management roles at Siemens starting in 1996 in both operating businesses and central divisions. From 2008 to 2015, he was a member of the Executive Team and CFO of Siemens Healthcare.

Mats Henriksson joined the Management Board of Fresenius Kabi on September 1, 1999. From 2001 to February 2012, he was responsible for the company’s Asia-Pacific region. From March 1, 2012, he served as Deputy Chairman of the Management Board of Fresenius Kabi, and on January 1, 2013 was appointed Chairman of the Management Board of Fresenius Kabi.

Dr. Gerd Krick, Chairman of the Supervisory Board of Fresenius, said: "Mats Henriksson played a major role in the development of Fresenius Kabi from the very beginning. From the acquisition and integration of Pharmacia & Upjohn, which became Fresenius Kabi in 1999, to the very successful expansion in Asia under his responsibility and the entry into the promising biosimilars business, he has made numerous important contributions to the growth of this Fresenius business segment. Mats Henriksson is handing over a well-managed business to his successor. On behalf of the entire Supervisory Board, I would like to thank him most sincerely. I wish him every success and the best for his future."

Wolfgang Kirsch, the designated Chairman of the Supervisory Board of Fresenius, said: "Fresenius has developed extremely dynamically and successfully over the past years, from a medium-sized company to a global healthcare group with sales of more than €36 billion today. With the recently presented growth strategy, the Management Board, under the proven leadership of Stephan Sturm, is setting the course for the company's sustained, successful further development. My colleagues on the Supervisory Board and I fully support this strategy, including the announced, ongoing and open review of the Group structure. Michael Sen is an experienced manager in the healthcare sector who complements our team very well. The Management Board of Fresenius is ideally positioned to successfully implement the strategy in the coming years and to continue Fresenius' growth story."

Stephan Sturm, CEO of Fresenius, said: "I have worked closely, trustfully and successfully with Mats Henriksson for many years. I thank him, and I personally wish him all the best. At the same time, I look forward to working with Michael Sen in the future. Fresenius Kabi's business addresses several attractive growth areas in medicine. It is and will remain of central strategic importance for our healthcare group. Together, we will work in the coming years to make this company even stronger – for the benefit of the growing number of patients who depend on our important drugs and products and for our shareholders."

Michael Sen said: "Fresenius Kabi is committed to improving the quality of life of patients around the world. In my future role, I would like to continue to put patient well-being at the center of everything we do and play my part in continuing the company's successful development. I am very much looking forward to working with Stephan Sturm and the entire team on the Management Board of Fresenius, and of course with my more than 40,000 new colleagues at Fresenius Kabi worldwide. With courage, dedication and creativity, we can and will still achieve a lot together."

The Supervisory Board of Fresenius Management SE also unanimously resolved to propose Susanne Zeidler (60), Chief Financial Officer of Deutsche Beteiligungs AG (DBAG) since November 2012, and Dr. Frank Appel (59), Chief Executive Officer of Deutsche Post DHL Group since February 2008, for election to the Supervisory Board of Fresenius Management SE.

Susanne Zeidler worked for the auditing and consulting firm KPMG between 1990 and 2010. Lastly, as a partner, she was responsible for KPMG's business with foundations and other non-profit organizations, which, as a qualified auditor and tax advisor, she had helped to establish from 2006 onwards. Prior to that, from 1990 to 1999, she was involved in the valuations of medium-sized and listed companies in various industries, and between 2000 and 2005 was the partner responsible for KPMG's internal audit review. Before joining the Management Board of DBAG, Susanne Zeidler was Managing Director at the headquarters of the international charity organization "Kirche in Not" ("Aid to the Church") from the beginning of 2011.

Dr. Frank Appel has worked for Deutsche Post DHL Group since 2000, initially as Managing Director Corporate Development, and from 2002 as Board Member responsible for Global Business Services and Key Account Management Global Customer Solutions. In 2005, he was responsible for the acquisition and integration of the British logistics company Exel. In February 2008, he was appointed Chief Executive Officer. A graduate chemist with a PhD in neurobiology, he began his professional career in 1993 at the management consultancy McKinsey, where he became a member of German Business Management in 1999 before joining Deutsche Post DHL Group.

As already announced in October 2020, Dr. Gerd Krick (82) will leave the Supervisory Boards of Fresenius Management SE and the listed Fresenius SE & Co. KGaA when his term ends at the close of the Annual General Meeting in May 2021. Wolfgang Kirsch (65), a member of the Supervisory Board of Fresenius Management SE since January 1, 2020, is to take over from him as Chairman of both Supervisory Boards. In recognition and deep appreciation of his long decades of accomplishment and invaluable work on behalf of Fresenius, Dr. Krick shall be named Honorary Chairman of both Supervisory Boards.

Klaus-Peter Müller (76) will be stepping down from the Supervisory Board of Fresenius Management SE at the end of his term in May 2021. At the listed Fresenius SE & Co. KGaA, Klaus-Peter Müller will stand for reelection to the Supervisory Board at the Annual General Meeting in May with the aim of chairing the Audit Committee for a further year.

Susanne Zeidler and Dr. Frank Appel proposed for election to the Supervisory Board of Fresenius Management SE

Michael Sen (52) will become the new Chief Executive Officer of Fresenius Kabi AG. The Supervisory Board of Fresenius Management SE has unanimously appointed him to the Management Board of Fresenius effective on April 12, 2021. He succeeds Mats Henriksson (53), who is leaving the company due to different views on Fresenius Kabi’s future direction.

Michael Sen was a member of the Management Board of Siemens AG from April 2017 to March 2020, where he was responsible for the healthcare business Siemens Healthineers and for Siemens’ energy business. Prior to that, from 2015 to 2017, he was Chief Financial Officer of E.ON SE. At the start of his professional career, Michael Sen completed an apprenticeship at Siemens in Berlin and then studied business administration at the Technical University of Berlin. After graduation, he took on various management roles at Siemens starting in 1996 in both operating businesses and central divisions. From 2008 to 2015, he was a member of the Executive Team and CFO of Siemens Healthcare.

Mats Henriksson joined the Management Board of Fresenius Kabi on September 1, 1999. From 2001 to February 2012, he was responsible for the company’s Asia-Pacific region. From March 1, 2012, he served as Deputy Chairman of the Management Board of Fresenius Kabi, and on January 1, 2013 was appointed Chairman of the Management Board of Fresenius Kabi.

Dr. Gerd Krick, Chairman of the Supervisory Board of Fresenius, said: "Mats Henriksson played a major role in the development of Fresenius Kabi from the very beginning. From the acquisition and integration of Pharmacia & Upjohn, which became Fresenius Kabi in 1999, to the very successful expansion in Asia under his responsibility and the entry into the promising biosimilars business, he has made numerous important contributions to the growth of this Fresenius business segment. Mats Henriksson is handing over a well-managed business to his successor. On behalf of the entire Supervisory Board, I would like to thank him most sincerely. I wish him every success and the best for his future."

Wolfgang Kirsch, the designated Chairman of the Supervisory Board of Fresenius, said: "Fresenius has developed extremely dynamically and successfully over the past years, from a medium-sized company to a global healthcare group with sales of more than €36 billion today. With the recently presented growth strategy, the Management Board, under the proven leadership of Stephan Sturm, is setting the course for the company's sustained, successful further development. My colleagues on the Supervisory Board and I fully support this strategy, including the announced, ongoing and open review of the Group structure. Michael Sen is an experienced manager in the healthcare sector who complements our team very well. The Management Board of Fresenius is ideally positioned to successfully implement the strategy in the coming years and to continue Fresenius' growth story."

Stephan Sturm, CEO of Fresenius, said: "I have worked closely, trustfully and successfully with Mats Henriksson for many years. I thank him, and I personally wish him all the best. At the same time, I look forward to working with Michael Sen in the future. Fresenius Kabi's business addresses several attractive growth areas in medicine. It is and will remain of central strategic importance for our healthcare group. Together, we will work in the coming years to make this company even stronger – for the benefit of the growing number of patients who depend on our important drugs and products and for our shareholders."

Michael Sen said: "Fresenius Kabi is committed to improving the quality of life of patients around the world. In my future role, I would like to continue to put patient well-being at the center of everything we do and play my part in continuing the company's successful development. I am very much looking forward to working with Stephan Sturm and the entire team on the Management Board of Fresenius, and of course with my more than 40,000 new colleagues at Fresenius Kabi worldwide. With courage, dedication and creativity, we can and will still achieve a lot together."

The Supervisory Board of Fresenius Management SE also unanimously resolved to propose Susanne Zeidler (60), Chief Financial Officer of Deutsche Beteiligungs AG (DBAG) since November 2012, and Dr. Frank Appel (59), Chief Executive Officer of Deutsche Post DHL Group since February 2008, for election to the Supervisory Board of Fresenius Management SE.

Susanne Zeidler worked for the auditing and consulting firm KPMG between 1990 and 2010. Lastly, as a partner, she was responsible for KPMG's business with foundations and other non-profit organizations, which, as a qualified auditor and tax advisor, she had helped to establish from 2006 onwards. Prior to that, from 1990 to 1999, she was involved in the valuations of medium-sized and listed companies in various industries, and between 2000 and 2005 was the partner responsible for KPMG's internal audit review. Before joining the Management Board of DBAG, Susanne Zeidler was Managing Director at the headquarters of the international charity organization "Kirche in Not" ("Aid to the Church") from the beginning of 2011.

Dr. Frank Appel has worked for Deutsche Post DHL Group since 2000, initially as Managing Director Corporate Development, and from 2002 as Board Member responsible for Global Business Services and Key Account Management Global Customer Solutions. In 2005, he was responsible for the acquisition and integration of the British logistics company Exel. In February 2008, he was appointed Chief Executive Officer. A graduate chemist with a PhD in neurobiology, he began his professional career in 1993 at the management consultancy McKinsey, where he became a member of German Business Management in 1999 before joining Deutsche Post DHL Group.

As already announced in October 2020, Dr. Gerd Krick (82) will leave the Supervisory Boards of Fresenius Management SE and the listed Fresenius SE & Co. KGaA when his term ends at the close of the Annual General Meeting in May 2021. Wolfgang Kirsch (65), a member of the Supervisory Board of Fresenius Management SE since January 1, 2020, is to take over from him as Chairman of both Supervisory Boards. In recognition and deep appreciation of his long decades of accomplishment and invaluable work on behalf of Fresenius, Dr. Krick shall be named Honorary Chairman of both Supervisory Boards.

Klaus-Peter Müller (76) will be stepping down from the Supervisory Board of Fresenius Management SE at the end of his term in May 2021. At the listed Fresenius SE & Co. KGaA, Klaus-Peter Müller will stand for reelection to the Supervisory Board at the Annual General Meeting in May with the aim of chairing the Audit Committee for a further year.